AI Article Synopsis
- About 40% of patients with non-small cell lung cancer (NSCLC) develop brain metastases, leading to significant health issues and complicated treatment needs.
- Immune checkpoint inhibitors (ICIs) have revolutionized NSCLC treatment, improving survival; however, their effectiveness in patients with brain metastases is not yet well-studied.
- This review highlights the current clinical evidence regarding ICIs for treating brain metastases in NSCLC and discusses the challenges of integrating these therapies into patient care.
Article Abstract
Approximately 40% of unselected non-small cell lung cancer (NSCLC) patients develop brain metastases (BMs) during their disease, with considerable morbidity and mortality. The management of BMs in patients with NSCLC is a clinical challenge and requires a multidisciplinary approach to gain effective intracranial disease control. Over the last decade, immune checkpoint inhibitors (ICIs) have emerged as a game-changer in the treatment landscape of advanced NSCLC, with significant improvements in survival outcomes, although patients with BMs are mostly underrepresented in randomized clinical trials. Moreover, the safety and activity of ICIs and radiotherapy combinations compared with single-agent or sequential modalities is still under evaluation to establish the optimal management of these patients. The aim of this review is to summarize the state-of-the-art of clinical evidence of ICIs intracranial activity and the main challenges of incorporating these agents in the treatment armamentarium of NSCLC patients with BMs.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9267075 | PMC |
| http://dx.doi.org/10.3390/ijms23137068 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!